--- title: "UnitedHealth Group (NYSE:UNH) Trading Down 3% After Analyst Downgrade" type: "News" locale: "en" url: "https://longbridge.com/en/news/263604298.md" description: "UnitedHealth Group's stock (NYSE:UNH) fell 3% after Deutsche Bank downgraded it from a buy to a hold rating, setting a price target of $333.00. The stock traded as low as $343.60, with a volume decline of 8% from its average. Despite this, other analysts have set higher price targets, with Mizuho raising theirs to $430.00. Institutional investors hold 87.86% of the stock. The company reported a quarterly EPS of $2.92, exceeding estimates, and announced a quarterly dividend of $2.21." datetime: "2025-10-30T20:52:59.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/263604298.md) - [en](https://longbridge.com/en/news/263604298.md) - [zh-HK](https://longbridge.com/zh-HK/news/263604298.md) --- > Supported Languages: [简体中文](https://longbridge.com/zh-CN/news/263604298.md) | [繁體中文](https://longbridge.com/zh-HK/news/263604298.md) # UnitedHealth Group (NYSE:UNH) Trading Down 3% After Analyst Downgrade UnitedHealth Group Incorporated (NYSE:UNH - Get Free Report)'s share price dropped 3% during mid-day trading on Thursday after Deutsche Bank Aktiengesellschaft downgraded the stock from a buy rating to a hold rating. Deutsche Bank Aktiengesellschaft now has a $333.00 price target on the stock. UnitedHealth Group traded as low as $343.60 and last traded at $344.5740. Approximately 11,368,248 shares were traded during mid-day trading, a decline of 8% from the average daily volume of 12,421,708 shares. The stock had previously closed at $355.26. Get **UnitedHealth Group** alerts: - Snowflake Stock Is on Fire—It’s Still Not Too Late to Buy UNH has been the topic of several other research reports. Mizuho lifted their price target on UnitedHealth Group from $300.00 to $430.00 and gave the stock an "outperform" rating in a report on Thursday, October 9th. Leerink Partners set a $410.00 price objective on shares of UnitedHealth Group and gave the company an "outperform" rating in a report on Wednesday. Oppenheimer reduced their price objective on shares of UnitedHealth Group from $400.00 to $325.00 and set an "outperform" rating on the stock in a report on Wednesday, July 30th. Piper Sandler reduced their price objective on shares of UnitedHealth Group from $423.00 to $417.00 and set an "overweight" rating on the stock in a report on Tuesday. Finally, Sanford C. Bernstein boosted their price target on shares of UnitedHealth Group from $379.00 to $433.00 and gave the stock an "outperform" rating in a research note on Wednesday, October 8th. Eighteen analysts have rated the stock with a Buy rating, nine have given a Hold rating and three have given a Sell rating to the company's stock. According to data from MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and an average target price of $397.12. **Check Out Our Latest Report on UNH** ## Hedge Funds Weigh In On UnitedHealth Group - UnitedHealth Group’s Recovery in Full Swing: Buy While It's Down A number of institutional investors and hedge funds have recently added to or reduced their stakes in UNH. Norges Bank acquired a new position in UnitedHealth Group in the second quarter valued at approximately $3,837,207,000. Nuveen LLC acquired a new stake in shares of UnitedHealth Group in the first quarter valued at approximately $3,846,764,000. Vanguard Group Inc. boosted its holdings in shares of UnitedHealth Group by 6.6% in the first quarter. Vanguard Group Inc. now owns 90,729,585 shares of the healthcare conglomerate's stock valued at $47,519,620,000 after acquiring an additional 5,583,343 shares during the period. Berkshire Hathaway Inc acquired a new stake in shares of UnitedHealth Group in the second quarter valued at approximately $1,572,193,000. Finally, Dodge & Cox boosted its holdings in shares of UnitedHealth Group by 117.7% in the second quarter. Dodge & Cox now owns 8,750,560 shares of the healthcare conglomerate's stock valued at $2,729,912,000 after acquiring an additional 4,730,192 shares during the period. 87.86% of the stock is owned by institutional investors and hedge funds. ## UnitedHealth Group Price Performance The company has a debt-to-equity ratio of 0.71, a current ratio of 0.82 and a quick ratio of 0.85. The company has a 50 day moving average price of $342.00 and a 200 day moving average price of $331.00. The firm has a market cap of $312.07 billion, a PE ratio of 17.98, a PEG ratio of 2.37 and a beta of 0.47. - Big Banks Are Setting the Tone as Earnings Season Kicks Off UnitedHealth Group (NYSE:UNH - Get Free Report) last released its quarterly earnings results on Tuesday, October 28th. The healthcare conglomerate reported $2.92 EPS for the quarter, topping the consensus estimate of $2.87 by $0.05. UnitedHealth Group had a return on equity of 19.23% and a net margin of 4.04%.The business had revenue of $113.16 billion during the quarter, compared to analysts' expectations of $113.19 billion. During the same quarter in the prior year, the business earned $7.15 earnings per share. The company's quarterly revenue was up 12.2% compared to the same quarter last year. Sell-side analysts expect that UnitedHealth Group Incorporated will post 29.54 EPS for the current fiscal year. ## UnitedHealth Group Announces Dividend The firm also recently disclosed a quarterly dividend, which was paid on Tuesday, September 23rd. Shareholders of record on Monday, September 15th were given a $2.21 dividend. The ex-dividend date was Monday, September 15th. This represents a $8.84 annualized dividend and a yield of 2.6%. UnitedHealth Group's dividend payout ratio is presently 46.14%. ## UnitedHealth Group Company Profile (Get Free Report) UnitedHealth Group Incorporated operates as a diversified health care company in the United States. The company operates through four segments: UnitedHealthcare, Optum Health, Optum Insight, and Optum Rx. The UnitedHealthcare segment offers consumer-oriented health benefit plans and services for national employers, public sector employers, mid-sized employers, small businesses, and individuals; health care coverage, and health and well-being services to individuals age 50 and older addressing their needs; Medicaid plans, children's health insurance and health care programs; and health and dental benefits, and hospital and clinical services, as well as health care benefits products and services to state programs caring for the economically disadvantaged, medically underserved, and those without the benefit of employer-funded health care coverage. ## See Also - Five stocks we like better than UnitedHealth Group - Industrial Products Stocks Investing - Hold Ratings, High Rewards? 3 Stocks That Could Defy Expectations - Trading Halts Explained - Investors Boost American Electric Power on AI Growth - How to Profit From Value Investing - Carrier Stock Looks Undervalued After Earnings Surprise _This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com._ ## Should You Invest $1,000 in UnitedHealth Group Right Now? Before you consider UnitedHealth Group, you'll want to hear this. MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and UnitedHealth Group wasn't on the list. While UnitedHealth Group currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys. View The Five Stocks Here ### Related Stocks - [UnitedHealth Group Incorporated (UNH.US)](https://longbridge.com/en/quote/UNH.US.md) ## Related News & Research - [Why UnitedHealth Stock (UNH) Is Rising Today — And What Raymond James Sees Next](https://longbridge.com/en/news/281349145.md) - [Wall Street's Most Accurate Analysts Give Their Take On 3 Health Care Stocks Delivering High-Dividend Yields](https://longbridge.com/en/news/281183048.md) - [INSTANT VIEW-Lilly gets FDA nod for oral obesity pill, analysts see strong uptake potential](https://longbridge.com/en/news/281409741.md) - [Skye Bioscience investor presentation spotlights nimacimab-semaglutide combo weight-loss data](https://longbridge.com/en/news/281411418.md) - [11:33 ETFitness, Health and Wellness Experts Team Up to 'Get Fit for No Kid Hungry' with New On-Demand Initiative](https://longbridge.com/en/news/281213207.md)